Notícias

Novo Nordisk claims Eli Lilly aired misleading ads comparing the pharma companies' respective weight-loss drugs, Wegovy and Zepbound.

The maker of Ozempic and Wegovy says its competitor is misleading consumers by citing outdated weight-loss data in advertisements.

Novo says Lilly's TV and social media campaigns cite outdated trial data to make Zepbound and Mounjaro look more effective than rival injections

By Maggie Fick LONDON, July 21 (Reuters) - Novo Nordisk said on Tuesday it was suing rival Eli Lilly in U.S. federal court, accusing the U.S. drugmaker of false advertising in claiming its weight-loss

(Bloomberg) -- Novo Nordisk A/S is suing Eli Lilly & Co. in US federal court, claiming that Lilly’s advertising for its blockbuster obesity shot Zepbound and diabetes injection Mounjaro is misleading as competition between the two drugmakers escalates.Most Read from BloombergYemen’s Houthis to Impose Maritime Blockade on Saudi ArabiaChina AI Sensation Moonshot’s Gamble on Big Models Pays OffTrump Vows 50% Tariff on Canadian Goods Using Depression-Era LawMoonshot’s Kimi K3 May Be More About Memor

Novo Nordisk has accused arch-rival Eli Lilly of peddling false claims about its weight-loss products in advertising campaigns, marking the latest...

The temperature was 92 degrees Fahrenheit. The sweat, profuse. And I was walking toward an exhibition about the “obesity experience” on London’s bustling riverside funded by a $220 billion pharmaceutical company.

Novo Nordisk (CPSE:NOVO B) and Fangzhou have launched Kyinsu®, the world's first once weekly basal insulin/GLP-1 RA combination therapy, in China. The product is being introduced through Fangzhou's AI driven Internet hospital, targeting broader access for people living with diabetes. The launch expands Novo Nordisk's presence in China by pairing a new treatment format with a digital care platform. Novo Nordisk, trading at DKK329.9 per share, is adding Kyinsu® to its portfolio at a time when...

Novo Nordisk wins EU approval for the first GLP-1 obesity tablet, expanding Wegovy's reach, but tougher competition keeps the broader investment outlook in focus.

Citi has raised its price target on Novo Nordisk (NYSE:NVO) to DKK330 ahead of second-quarter results on 5 August, citing the strength of the Danish drugmaker's Wegovy pill launch. The broker lifted its 2026 sales and operating income estimates by 4% to 5%, and its earnings per share...

The European Commission approved Novo Nordisk A/S’ Wegovy pill, a once-daily oral semaglutide 25 mg treatment for adults with obesity or overweight with at least one weight-related comorbidity. The approval makes Wegovy the first GLP-1 receptor agonist available in tablet...

Viking's latest program seeks to push the envelope in weight loss efficacy.

There's a good reason why investors are focused on Eli Lilly's GLP-1 business, but there's more going on at the company.

Novo Nordisk is finally getting one up on its biggest rival.

The FDA just approved the first once-daily oral PCSK9 pill, and five major stocks now sit in the crosshairs. Not all of them come out ahead, and the biggest surprise winner may not be the company that makes the drug.

The weight-loss boom has created one of the market's biggest opportunities — and some of its most punishing failures.

Despite an FDA crackdown and numerous pharma lawsuits, nearly 1 in 5 patients are taking cheaper weight-loss alternatives despite the risks.

All three can be bought on the dip.

Novo Nordisk (NVO) closed the most recent trading day at $51.48, moving +1.82% from the previous trading session.

Novo Nordisk (NYSE:NVO) received European Commission marketing authorization for its oral Wegovy pill for weight management. The approval covers the European Union and represents the first GLP-1 receptor agonist in pill form cleared for this use in the region. This decision follows growing use of obesity therapies in the U.S. and other key markets. Novo Nordisk is already a major player in diabetes and obesity care, and the oral Wegovy pill gives the company another way to reach patients...

Novo Nordisk wins EC approval for a once-daily oral Wegovy pill for obesity, expanding its EU franchise with the first GLP-1 tablet for weight management.

Novo Nordisk is relying on first-mover advantage in the obesity pill arena to close the gap on Eli Lilly.

European equities traded in the US as American depositary receipts were slightly lower on Thursday m

PFE trades below key moving averages as investors weigh fading COVID sales against pipeline growth, acquisitions and a low valuation with a high dividend.

FDA advisors will debate the merits of seven peptides next week. The discussion could have an impact on Eli Lilly and Novo Nordisk.

Faced with the dual pressures of shifting consumer habits and emerging health trends, General Mills finds itself in a challenging market position.

Novo Nordisk is under fresh scrutiny as analysts adjust their price targets, with a fair value estimate moving from DKK 309.77 to DKK 316.91. This shift reflects a broader rethink of growth and risk assumptions, as analysts weigh more cautious revenue expectations against their updated view of what the stock might be worth. As you read on, you will see how to interpret these changing targets and what they could mean for your own view of Novo Nordisk. Stay updated as the Fair Value for Novo...

Vivani Medical (NASDAQ:VANI) said it is preparing to begin human testing of its semaglutide implant in August and highlighted a recently announced agreement with Novo Nordisk to evaluate the company’s implant technology. Adam Mendelsohn, co-founder, CEO and director of Vivani Medical, said the past

Wegovy Pill Wins Big as Eli Lilly Rollout Lags

Wegovy captured about 89% of weekly prescriptions.